MORGAN STANLEY - JOUNCE THERAPEUTICS INC ownership

JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 102 filers reported holding JOUNCE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 1.0%.

Quarter-by-quarter ownership
MORGAN STANLEY ownership history of JOUNCE THERAPEUTICS INC
ValueSharesWeighting
Q1 2023$221,861
-87.9%
119,925
-92.8%
0.00%
Q4 2022$1,840,297
-53.1%
1,657,925
-1.2%
0.00%
-100.0%
Q3 2022$3,928,000
-20.4%
1,678,448
+3.0%
0.00%0.0%
Q2 2022$4,937,000
-52.4%
1,629,922
+6.8%
0.00%0.0%
Q1 2022$10,363,000
+3412.9%
1,526,288
+4212.4%
0.00%
Q4 2021$295,000
+68.6%
35,393
+49.3%
0.00%
Q3 2021$175,000
-71.6%
23,705
-73.9%
0.00%
Q2 2021$617,000
+254.6%
90,731
+435.1%
0.00%
Q1 2021$174,000
-28.4%
16,956
-51.2%
0.00%
Q4 2020$243,000
-12.6%
34,729
+2.1%
0.00%
Q3 2020$278,000
+65.5%
33,999
+39.8%
0.00%
Q2 2020$168,000
-20.0%
24,328
-45.0%
0.00%
Q1 2020$210,000
-49.3%
44,258
-6.5%
0.00%
Q4 2019$414,000
+172.4%
47,360
+3.6%
0.00%
Q3 2019$152,000
+111.1%
45,733
+212.2%
0.00%
Q2 2019$72,000
-28.7%
14,650
-9.4%
0.00%
Q1 2019$101,000
-74.9%
16,162
-86.5%
0.00%
Q4 2018$403,000
+27.1%
119,756
+145.6%
0.00%
Q3 2018$317,000
-65.4%
48,753
-59.2%
0.00%
Q2 2018$915,000
+7.8%
119,525
+214.5%
0.00%
Q1 2018$849,000
+39.9%
38,007
-20.3%
0.00%
Q4 2017$607,000
-59.4%
47,690
-50.3%
0.00%
Q3 2017$1,494,000
+758.6%
95,921
+676.1%
0.00%
Q2 2017$174,000
-68.7%
12,360
-51.0%
0.00%
Q1 2017$556,00025,2180.00%
Other shareholders
JOUNCE THERAPEUTICS INC shareholders Q3 2022
NameSharesValueWeighting ↓
TRV GP II, LLC 10,230,349$63,428,00041.36%
TRV GP III, LLC 3,048,780$18,902,0009.26%
Omega Fund Management, LLC 1,059,930$6,572,0001.39%
Alambic Investment Management, L.P. 50,622$314,0000.13%
Spark Investment Management LLC 244,300$1,514,0000.07%
ALGERT GLOBAL LLC 14,182$88,0000.05%
Redmile Group, LLC 254,590$1,578,0000.05%
Granahan Investment Management 125,533$778,0000.04%
GSA CAPITAL PARTNERS LLP 38,602$239,0000.02%
Frontier Wealth Management LLC 27,099$168,0000.02%
View complete list of JOUNCE THERAPEUTICS INC shareholders